| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 07/27/2011 | CN101229130B Isomorellic acid polylactic acid nano particle preparation and preparing method thereof |
| 07/27/2011 | CN101214275B Compound red sage root extended release formulation and preparation thereof |
| 07/27/2011 | CN101181337B High ester catechin capsule for curing mammary cancer and preparation method thereof |
| 07/27/2011 | CN101168594B Polyglycol active derivative with oligopeptide as framework, preparation method thereof and conjugate of with pharmaceutical molecule |
| 07/27/2011 | CN101108166B Quantitative nano aerosol and method of manufacturing the same |
| 07/27/2011 | CN101052384B Non-aqueous transdermal absorption preparation containing non-steroid antiphlogistic analgesic |
| 07/27/2011 | CN101045062B Polyenephophatidylcholine enteric coated preparation, its preparing method and application |
| 07/27/2011 | CN101039699B Methods and compositions for reducing toxicity of a pharmaceutical compound |
| 07/26/2011 | US7985601 Drug delivery vehicle; tissue engineering |
| 07/26/2011 | US7985427 geometric shaped enclosures comprising layers of polymers containing drugs, used as drug delivery devices, for sustained release in the intestines; capsules |
| 07/26/2011 | US7985421 Sustained release formulations of guaifenesin and additional drug ingredients |
| 07/26/2011 | US7985420 Sustained release of guaifenesin combination drugs |
| 07/26/2011 | US7985401 Peptides whose uptake by cells is controllable |
| 07/26/2011 | CA2784919A1 Compositions and methods relating to argininosuccinate synthetase |
| 07/26/2011 | CA2535401C Emulsive composition containing dapsone |
| 07/26/2011 | CA2502870C High-molecular weight derivatives of camptothecins |
| 07/26/2011 | CA2499814C Strontium compound for treatment of sub-dermal soft tissue pain |
| 07/26/2011 | CA2481325C Anti-hiv composition, production method thereof and medicament |
| 07/26/2011 | CA2422974C Medicaments based on progestins for dermal use |
| 07/26/2011 | CA2405169C Devices and formulations |
| 07/26/2011 | CA2385140C Biodegradable elastomer and methods of preparing same |
| 07/26/2011 | CA2376346C Nucleic acid molecule comprising a nucleic acid sequence which codes for a haemocyanin, and comprising at least one intron sequence |
| 07/26/2011 | CA2333162C Process for producing composite preparation containing nucleic acid |
| 07/26/2011 | CA2222757C Modified/chimeric superantigens and their use |
| 07/21/2011 | WO2011087804A2 Peptide-polynucleotide compositions, and methods for transfecting a cell with dna and treatment of neurodegenerative disease |
| 07/21/2011 | WO2011087441A1 A pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one with improved storage and solubility properties |
| 07/21/2011 | WO2011087024A1 Insulin preparation |
| 07/21/2011 | WO2011086577A2 Pharmaceutical composition of moxifloxacin and its pharmaceutically acceptable salts |
| 07/21/2011 | WO2011086331A2 Method for manufacturing capsules having controlled head |
| 07/21/2011 | WO2011086146A1 Halogenated ether complex |
| 07/21/2011 | WO2011086143A2 Liver targeting molecules |
| 07/21/2011 | WO2011086093A2 Pharmaceutical compositions for oral administration of insulin peptides |
| 07/21/2011 | WO2011085720A1 Biologically active molecules for influencing virus-, bacteria-, parasite-infected cells and/or tumor cells and method for the use thereof |
| 07/21/2011 | WO2011085474A1 Apparatus and method for delivering honey bee brood pheromone into a hive |
| 07/21/2011 | WO2011060195A3 Topical etoricoxib formulation comprising an eutectic mixture of permeation enhancers |
| 07/21/2011 | WO2011031018A3 Water-soluble drug delivery system allowing slow release |
| 07/21/2011 | WO2011026041A9 Sdf-1 delivery for treating ischemic tissue |
| 07/21/2011 | WO2011018800A3 In-situ gel forming solution for ocular drug delivery |
| 07/21/2011 | WO2011010084A3 Cyclosporin conjugates |
| 07/21/2011 | US20110178242 Methods for Forming Polymer-Drug Conjugates |
| 07/21/2011 | US20110178207 Particle-stabilised emulsions |
| 07/21/2011 | US20110178184 Hydrogel |
| 07/21/2011 | US20110178183 Use Of Polyether-Based And Vinyl Monomer-Based Copolymers As Binders For Dosing Forms Comprising Solid Active Ingredients |
| 07/21/2011 | US20110178182 Enriched nanostructure composition |
| 07/21/2011 | US20110178044 Transdermal administration of hydrophilic drugs using permeation enhancer composition |
| 07/21/2011 | US20110178006 Method for administering glp-1 molecules |
| 07/21/2011 | US20110177997 Cross-Beta Silk Genes |
| 07/21/2011 | US20110177595 Multipotent Adult Stem Cells, Sources Thereof, Methods of Obtaining and Maintaining Same, Methods of Differentiation Thereof, Methods of Use Thereof and Cells Derived Thereof |
| 07/21/2011 | US20110177176 Gel-Based Compositions and Methods of Making Same |
| 07/21/2011 | US20110177168 Composition |
| 07/21/2011 | US20110177167 Hydrophilic/Lipophilic Polymeric Matrix Dosage Formulation |
| 07/21/2011 | US20110177157 Compositions for Controlled Delivery of Pharmaceutically Active Compounds |
| 07/21/2011 | US20110177152 Drug/Drug Delivery Systems For The Prevention And Treatment Of Vascular Disease |
| 07/21/2011 | US20110177139 Solid microstructure that enables multiple controlled release and method of maufacturing same |
| 07/21/2011 | US20110177110 Compositions comprising cationic microparticles and hcv e1e2 dna and methods of use thereof |
| 07/21/2011 | US20110177102 Targeted double stranded rna mediated cell killing |
| 07/21/2011 | US20110177100 Targeting pax2 for the induction of defb1-mediated tumor immunity and cancer therapy |
| 07/21/2011 | US20110177068 Pharmaceutical preparation comprising an antibody against the egf receptor |
| 07/21/2011 | US20110177066 Prevention and treatment of amyloidogenic diseases |
| 07/21/2011 | US20110176997 Method to make porous materials and their applications |
| 07/21/2011 | US20110176994 Buoyant Polymer Particles for Delivery of Therapeutic Agents to the Central Nervous System |
| 07/21/2011 | CA2822220A1 Solid-forming local anesthetic formulations for pain control |
| 07/21/2011 | CA2787260A1 Methods and compositions for nanoparticle-mediated cancer cell-targeted delivery |
| 07/21/2011 | CA2787115A1 Flurane complex |
| 07/21/2011 | CA2786953A1 Pharmaceutical compositions for oral administration of insulin peptides |
| 07/21/2011 | CA2786671A1 Formulations of nano-carriers and methods of preparing the same |
| 07/21/2011 | CA2786660A1 Liver targeting molecules |
| 07/21/2011 | CA2786330A1 A pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one with improved storage and solubility properties |
| 07/21/2011 | CA2786181A1 Process for the preparation of pharmaceutical compositions for the sustained release of somatostatin analogs |
| 07/21/2011 | CA2784671A1 Oxyntomodulin peptide analogue |
| 07/21/2011 | CA2784668A1 Oxyntomodulin peptide analogue |
| 07/21/2011 | CA2784033A1 A method of treating a staphylococcus infection in a patient having a low-level pathogenic pseudomonas aeruginosa infection |
| 07/20/2011 | EP2345724A1 G-CSF analog compositions and methods |
| 07/20/2011 | EP2345721A1 Recombinant gelatin in vaccines |
| 07/20/2011 | EP2345673A1 Humanized anti-granulocyte MN-3 antibody and uses thereof |
| 07/20/2011 | EP2345427A1 Fluoran complex |
| 07/20/2011 | EP2345426A1 Composite organic compound powder for medical use, method for producing same and suspension of same |
| 07/20/2011 | EP2345419A1 Mucosal vaccine using cationic nanogel |
| 07/20/2011 | EP2345414A1 Tacrolimus preparation for external applications |
| 07/20/2011 | EP2345413A2 Composition and use of a long-acting oral bioadhesive endoparasiticide gel based on doramectin |
| 07/20/2011 | EP2345410A1 Controlled release pharmaceutical composition |
| 07/20/2011 | EP2345406A1 Use of dimer diol in the production of bodily fluid substitutes |
| 07/20/2011 | EP2344556A1 Swellable biodegradable polymeric matrices and methods |
| 07/20/2011 | EP2344547A1 Polysaccharides containing carboxyl functional groups substituted by a hydrophobic alcohol derivative |
| 07/20/2011 | EP2344203A2 Method for the treatment of radiation-induced neutropenia by administration of a multi-pegylated granulocyte colony stimulating factor (g-csf) variant |
| 07/20/2011 | EP2344202A2 Mucosal delivery of therapeutic molecules, proteins, or particles coupled to ceramide lipids |
| 07/20/2011 | EP2344201A1 Oligomer-protease inhibitor conjugates |
| 07/20/2011 | EP2344200A2 Modified therapeutics peptides, methods of their preparation and use |
| 07/20/2011 | EP2344199A1 Polymer conjugates of thymosin alpha 1 peptides |
| 07/20/2011 | EP2344198A2 Lipid based pharmaceutical preparations for oral and topical application; their compositions, methods, and uses thereof |
| 07/20/2011 | EP2344197A1 Lactose and cellulose-based tableting aid |
| 07/20/2011 | EP2344183A1 Dosage forms that facilitate rapid activation of zymogen |
| 07/20/2011 | EP2344165A2 Pharmaceutical compositions comprising boronic acid compounds |
| 07/20/2011 | EP2344163A1 Oral formulation |
| 07/20/2011 | EP2344138A2 Use of polyether-based and vinyl monomer-based copolymers as binders for dosing forms comprising solid active ingredients |
| 07/20/2011 | EP2344137A1 Method for making cetirizine tablets |
| 07/20/2011 | EP2344134A2 Nanocarriers for drug delivery |
| 07/20/2011 | EP2344129A1 Aerosol fluoroquinolone formulations for improved pharmacokinetics |
| 07/20/2011 | EP2343973A1 Novel dipeptidyl peptidase (dp-iv) compounds |
| 07/20/2011 | EP2343971A1 Colorless antiseptic solution for skin use |